Core Insights - ALK's full-year results for 2025 exceeded expectations, driven by strong Q4 performance and ongoing commercial momentum [1] - The company anticipates sustained organic revenue growth of 11-15% and an EBIT margin of around 25% by 2026, aligning with long-term targets [1][14] - A dividend payment of DKK 355 million, approximately 30% of net profit after tax, is recommended to reward shareholders [1][6] Financial Performance - Q4 2025 revenue reached DKK 1,733 million, a 17% increase compared to the previous year, while full-year revenue grew by 15% to DKK 6,312 million [3][4] - EBIT for Q4 increased by 88% to DKK 387 million, with a margin of 22%, and for the full year, EBIT rose by 53% to DKK 1,654 million, achieving a margin of 26% [3][4] - Free cash flow was positive at DKK 1,432 million, significantly improved from a negative DKK 204 million the previous year [4] Product Performance - Tablet sales increased by 15% to DKK 910 million in Q4, with notable growth in Europe and North America [4] - Sales of SCIT/SLIT drops rose by 11% to DKK 607 million, while anaphylaxis and other products saw a 50% increase to DKK 216 million [4] - Pediatric launches of ACARIZAX and ITULAZAX exceeded expectations, with strong prescriber adoption [5] Strategic Outlook - The company plans to continue double-digit revenue growth and higher earnings in 2026, with a focus on treating more patients with AIT and anaphylaxis products [7][8] - The EBIT margin may experience slight pressure due to a decline in gross margin, offset by higher partner-related sales at lower margins [8] - Ongoing partnerships and clinical trials are expected to contribute positively to future growth [5]

Core Viewpoint - ALK reported a strong Q2 performance with a 12% organic revenue growth and a 41% increase in operating profit, leading to an upgraded full-year revenue outlook [1][6]. Q2 Performance Highlights - Revenue for Q2 2025 reached DKK 1,527 million, reflecting a 12% growth in local currency and an 11% growth in reported currency [3]. - Operating profit (EBIT) for Q2 was DKK 375 million, marking a 41% increase in local currency and a 42% increase in reported currency, with an EBIT margin of 25% [3]. - For H1 2025, revenue totaled DKK 3,049 million, with a consistent 12% growth in both local and reported currencies [3]. Financial Highlights - Full-year revenue outlook has been upgraded to a growth expectation of 12-14% in local currencies, previously estimated at 9-13% [6][13]. - Tablet sales grew by 16% to DKK 831 million, with Europe and North America showing significant growth rates of 17% and 32%, respectively [6]. - Sales of Other products and services increased by 30% to DKK 215 million, while anaphylaxis revenue surged by 56% [6]. Strategic Initiatives - The launch of new products, including the house dust mite tablet and the neffy adrenaline nasal spray, has exceeded initial market expectations [7][8]. - A dedicated pediatric sales force in the USA has been fully deployed, contributing to growth initiatives [7][8]. - Patient recruitment for the clinical phase 2 trial with the peanut allergy tablet was completed ahead of schedule [7].